Ethical Issues in Cell and Gene Therapy




The global market for cell and gene-based therapies is expected to surpass the $20 billion USD mark by 2025, with an annual growth rate of 21%. The main targets for cell – based therapies are high impact disease areas with significant incurable needs, including cancer, heart disease, neurodegenerative diseases, musculoskeletal disorders and autoimmune diseases. Gene therapies should then not be rushed to market, but companies should gather the required data about the impact of therapy in human community with the appropriate duration of follow-up to allow proper evaluation by payers. In addition, it is key to think about potential reimbursement of the techniques and also the pricing strategies, including risk sharing, as soon as the early clinical development phase



 





 





 


  • Autoimmune Disease Stem Cell Treatment
  • Blood and Skin Diseases
  • Lymphoma
  • Biosafety and rDNA Guidelines
  • Governing Stem Cell Therapy and Fundings
  • Ethical Issues in Stem Cell Research
  • Key Ethical Issues in Embryonic Stem Cell
  • IPR

Related Conference of Ethical Issues in Cell and Gene Therapy

June 16-17, 2025

21st Global Summit on Stem Cell & Regenerative Medicine

Frankfurt, Germany
July 21-22, 2025

18th World Congress on Stem Cell Research

Barcelona, Spain
September 25-26, 2025

6th Annual summit on Cell Signaling and Cancer Therapy

Montreal, Canada

Ethical Issues in Cell and Gene Therapy Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in